As of 4:00pm ET
| +0.21 / +1.53%|
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 17.00, with a high estimate of 20.00 and a low estimate of 14.00. The median estimate represents a +21.69% increase from the last price of 13.97.
The current consensus among 8 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.